Cargando…

A systematic literature review of prognostic factors in patients with HR+/HER2− advanced breast cancer in Japan

BACKGROUND: Breast cancer is the most prevalent cancer in women in Japan and the fifth in mortality. This systematic review summarized the evidence for prognostic factors for patients with HR+/HER2− advanced and metastatic breast cancer in Japan. METHODS: MEDLINE and EMBASE were searched with keywor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattori, Masaya, Novick, Diego, Takaura, Kana, Tanizawa, Yoshinori, Kawaguchi, Tsutomu, Haro, Josep Maria, Monistrol-Mula, Anna, Onishi, Akira, Iwata, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491537/ https://www.ncbi.nlm.nih.gov/pubmed/34417808 http://dx.doi.org/10.1093/jjco/hyab131

Ejemplares similares

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
por: Nozawa, K., et al.
Publicado: (2023)

Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
por: Novick, Diego, et al.
Publicado: (2022)

Nutrition, Bioenergetics, and Metabolic Syndrome
por: García-García, Francesc Josep, et al.
Publicado: (2020)

Methods for Stratification and Validation Cohorts: A Scoping Review
por: Torres Moral, Teresa, et al.
Publicado: (2022)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
por: Isogai, Ayaka, et al.
Publicado: (2023)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

The impact of COVID-related perceived stress and social support on generalized anxiety and major depressive disorders: moderating effects of pre-pandemic mental disorders
por: Monistrol-Mula, Anna, et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
por: Cristofanilli, Massimo, et al.
Publicado: (2022)

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer
por: Ni, Hua, et al.
Publicado: (2021)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
por: Novick, Diego, et al.
Publicado: (2016)

Facilitative effect of repetitive presentation of one stimulus on cortical responses to other stimuli in macaque monkeys – a possible neural mechanism for mismatch negativity
por: Takaura, Kana, et al.
Publicado: (2016)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan
por: Yoshimura, Akiyo, et al.
Publicado: (2018)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick, Diego, et al.
Publicado: (2015)

Antidepressant medication treatment patterns in Asian patients with major depressive disorder
por: Novick, Diego, et al.
Publicado: (2015)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)

HR(+)/HER2(−) de novo metastatic breast cancer: a true peculiar entity?
por: Torrisi, Rosalba, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
por: Sawaki, Masataka, et al.
Publicado: (2023)

Mismatch negativity in common marmosets: Whole-cortical recordings with multi-channel electrocorticograms
por: Komatsu, Misako, et al.
Publicado: (2015)

Combined anti-HER2 and hormonal treatment in a patient with HR(+)HER2(+) clear-cell uterine carcinoma: A case report
por: Gordeeva, Olga O., et al.
Publicado: (2021)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0iph8qb7fcc8lcjrgtnvtm8nll